Vir Biotechnology (VIR) Stock: Buy, Sell, or Hold?
VIR - Vir Biotechnology, Inc. Common Stock
$10.51
0.08 (0.77%)
â˛
5d:
+5.52%
30d:
-1.96%
90d:
+19.43%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 04, 2026
11d
Get Alerted When VIR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: VIR is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: VIR is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: VIR is currently trading at $10.51, which is considered slightly low relative to its 30-day fair value range of $10.40 to $11.32.
Technical Outlook: Technically, VIR is in a strong uptrend. Immediate support is located at $9.91, while resistance sits at $11.82.
Market Sentiment: VIR scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $21.00 (+101.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, VIR is in a strong uptrend. Immediate support is located at $9.91, while resistance sits at $11.82.
Market Sentiment: VIR scores 38/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $21.00 (+101.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$10.40 -
$11.32
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (38/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 101.3% below Wall St target ($21.00)
- WARNING: Composite score 47/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$10.40 -
$11.32
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$9.91
Resistance Level
$11.82
Current Trend
Strong Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.19
Wall Street Target
$21.00
(+101.3%)
Revenue Growth (YoY)
19582.5%
Earnings Growth (YoY)
58.5%
Profit Margin
-83.0%
Share & Embed Analysis
Last updated: October 23, 2026 2:00 PM ET
Data refreshes hourly during market hours. Next update: 3:00 PM
Data refreshes hourly during market hours. Next update: 3:00 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is VIR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals IâĻ |
STRONG BUY
32 analysts |
$571 | 58 HOLD |
|
ALNY
Alnylam Pharmaceuticals âĻ |
STRONG BUY
30 analysts |
$369 | 52 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
27 analysts |
$436 | 38 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
21 analysts |
$307 | 51 HOLD |
|
RYTM
Rhythm Pharmaceuticals IâĻ |
STRONG BUY
18 analysts |
$144 | 75 BUY |
